AGEN, a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Leerink Global Biopharma Conference on March 11th - 13th in Miami Beach, Florida. The fireside chat will take place at 2:30 p.m. ET on March 11th.
What are they working on?:
Agenus is focusing on immuno-oncology, conducting Phase 2 trials with botensilimab in melanoma, MSS colorectal cancer (with balstilimab), and pancreatic cancer (with chemotherapy). They're also developing balstilimab, a PD-1 inhibitor, across various cancers, including cervical cancer in Phase 2 trials. AGEN2373, an anti-CD137 agonist, is in Phase 1 trials for solid tumors, showcasing Agenus's commitment to advancing cancer treatments through innovative therapies
POSSIBLE SELL CLIMAX HERE.
If we break below, I will look for another Buy opportunity at the .63 area.
What are they working on?:
Agenus is focusing on immuno-oncology, conducting Phase 2 trials with botensilimab in melanoma, MSS colorectal cancer (with balstilimab), and pancreatic cancer (with chemotherapy). They're also developing balstilimab, a PD-1 inhibitor, across various cancers, including cervical cancer in Phase 2 trials. AGEN2373, an anti-CD137 agonist, is in Phase 1 trials for solid tumors, showcasing Agenus's commitment to advancing cancer treatments through innovative therapies
POSSIBLE SELL CLIMAX HERE.
If we break below, I will look for another Buy opportunity at the .63 area.
Comment:
according to 8k filing, Details about Agenus Inc.'s clinical milestones and other significant developments will be discussed with investors during a special shareholder meeting scheduled for April 3, 2024. This meeting will address the proposed reverse stock split and other relevant topics to the company's future and investment opportunities.
Trade active:
Snagged some more cheapies at $0.63. now sitting with my pole in the water.
Trade active:
Will Continue to accumulate at the low .55-.60 cent range, Agenus Inc. announced that the first preclinical data for BMS-986442 (AGEN1777) will be presented at the AACR Meeting in San Diego, CA, from April 5-10, 2024. BMS-986442 has shown superior immune activation both as a monotherapy and in combination with PD-(L)1 blockers, outperforming traditional TIGIT antibodies in non-clinical assays. This Fc-enhanced, bispecific antibody targets TIGIT and CD96 immune checkpoint receptors, utilizing Agenus’ proprietary Fc-engineering platform for novel mechanisms of action beyond current anti-TIGIT therapies. Dr. Dhan Chand, Vice President of Research, highlighted the potential of BMS-986442 to overcome the limitations faced by conventional TIGIT antibodies in clinical settings through its innovative approach.
Trade active:
Picked up some more here.
Comment:
.53 cents